IN BRIEF: CRISM confident in ChemoSeed as targets trial approval
CRISM Therapeutics Corp - British Virgin Islands-based pharmaceutical firm - As the firm held its annual general meeting, Chair Nermeen Varawalla says the firm must attract, retain and incentivise the best people as it continues to seek further validation for its novel delivery method. "[We] are confident that ChemoSeed has the potential to transform treatment for patients with solid-tumour cancers," Chair Varawalla continues. ChemoSeed is an implantable biodegradable drug delivery technology designed for the sustained delivery of chemotherapy directly into cancer tissue. Chair Varawalla says the company is focused on gaining trial approval from the UK Medicines & Healthcare products Regulatory Agency in glioblastoma and progressing towards dosing first patients in early 2026. Read More